CRHR1 rs110404: Stress Response and Cortisol Regulation
The genetic variant rs110404 is a single nucleotide polymorphism located within the CRHR1 gene, which encodes corticotropin-releasing hormone receptor 1. This variant forms part of an extended haplotype block linked to hypothalamic-pituitary-adrenal (HPA) axis activity and individual differences in cortisol reactivity. Scientific studies have investigated whether alleles at this locus moderate susceptibility to anxiety and stress-related conditions, although the overall clinical evidence remains limited.
What each genotype means
Typical stress and cortisol reactivity
You carry two copies of the common G allele in the CRHR1 gene. In published research, this genotype has been evaluated in relation to standard hypothalamic-pituitary-adrenal (HPA) axis regulation and cortisol output under stress. However, current evidence is limited and mixed, with observed associations frequently depending on early-life environmental factors rather than genotype alone.
Carried by approximately 30% to 35% of people of European ancestry, and common across many global populations.
Intermediate cortisol stress response
You carry one copy of the G allele and one copy of the minor A allele in the CRHR1 gene. Research suggests this heterozygous genotype is associated with intermediate cortisol reactivity and stress hormone response profiles compared to homozygous individuals. Because findings across studies are correlational and show limited statistical consensus, this does not indicate an altered medical risk.
Carried by roughly 45% to 50% of individuals in European populations.
Altered cortisol reactivity profile
You carry two copies of the minor A allele in the CRHR1 haplotype region. Published behavioral and neuroendocrine studies have statistically linked this genotype to altered stress reactivity and modified cortisol secretion during laboratory stressors. The evidence base remains limited, and this genetic pattern is not diagnostic of any psychiatric or endocrine disorder.
Carried by approximately 15% to 20% of people of European ancestry, with varying frequencies across other global ancestries.
Genomic Location and Variant Characteristics
The single nucleotide polymorphism rs110404 is situated within the CRHR1 gene on chromosome 17. It represents an intronic variation involving an exchange between adenine (A) and guanine (G) alleles. Because it resides in a non-coding region of the gene, rs110404 does not alter the amino acid sequence of the resulting protein directly. Instead, researchers study it as a tagging marker for a broader linkage disequilibrium block that spans key regulatory regions of the corticotropin-releasing hormone receptor locus. Variants in this cluster can influence gene transcription rates, alternative splicing, or chromatin accessibility, thereby potentially modulating how strongly the receptor responds to neuroendocrine stimulation. Genomic databases such as dbSNP catalogue rs110404 as a common, naturally occurring polymorphism found throughout global human populations.
The Biological Role of the CRHR1 Receptor
The CRHR1 gene codes for corticotropin-releasing hormone receptor 1, a class B G-protein coupled receptor abundant in the anterior pituitary gland, cerebral cortex, hippocampus, and amygdala. When the brain perceives a physical or psychological stressor, the hypothalamus secretes corticotropin-releasing hormone (CRH). Binding of CRH to CRHR1 triggers intracellular signaling cascades, primarily through cyclic adenosine monophosphate (cAMP) production, prompting the pituitary release of adrenocorticotropic hormone (ACTH). ACTH travels via the bloodstream to stimulate the adrenal cortex to synthesize and release cortisol. Consequently, CRHR1 is a central gateway for initiating the mammalian hypothalamic-pituitary-adrenal (HPA) axis stress response. Alterations in CRHR1 expression or receptor sensitivity can therefore modify the physiological and emotional trajectory of acute and prolonged stress reactivity.
Scientific Research and Strength of Evidence
A substantial body of candidate gene literature has examined rs110404 alongside closely linked variants like rs110402 and rs7209436 in relation to stress physiology. Several gene-by-environment (GxE) interaction studies have reported that specific haplotypes carrying rs110404 alleles moderate the relationship between early-life stress and the risk for adult depression or anxiety disorders. In neuroendocrine challenge tests, such as the dexamethasone/CRH suppression test, different genotypes have correlated with varying peak cortisol outputs and recovery trajectories. However, the evidence supporting a direct, causative role for rs110404 is categorized as limited. Large-scale genome-wide association studies (GWAS) often show modest or context-dependent associations rather than robust, standalone effects. Findings frequently depend on specific ancestral cohorts, interaction with traumatic experiences, or co-inheritance of other stress-related loci like FKBP5.
Population Distribution and Allele Diversity
Data from large genomic resources, such as the Genome Aggregation Database (gnomAD), indicate that rs110404 is a common polymorphism with varying allele distributions worldwide. In populations of European ancestry, the minor allele frequency is approximately 0.41, meaning that both homozygous and heterozygous genotypes are routinely observed in healthy cohorts. Frequency metrics can vary considerably in other continental groups, with distinct allele prevalences documented in African, East Asian, and South Asian populations. Because the surrounding genomic architecture on chromosome 17 includes extensive structural variation and complex linkage patterns, the functional implications of rs110404 may differ across backgrounds, underscoring why genetic associations identified in one population group cannot be automatically generalized to others.
Practical Implications and Clinical Perspective
Knowledge of an individual's rs110404 genotype carries educational and research interest, but it cannot be used as a standalone diagnostic tool for mood disorders, anxiety, or adrenal dysfunction. Complex traits like stress resilience and emotional well-being are polygenic, shaped by thousands of minor genetic variants acting in concert with lifetime environmental factors, lifestyle, and social support. No clinical guideline recommends altering psychiatric care, lifestyle interventions, or therapeutic plans based on this single marker alone. Although researchers have explored synthetic CRHR1 antagonists as potential treatments for depressive and stress-related conditions, these remain experimental or investigational. Consumers should never adjust medications or treatment regimens without the direct guidance of a licensed physician or pharmacist.
How common is this variant?
The minor allele frequency for rs110404 is approximately 0.41 in European populations according to gnomAD, resulting in common representation of all three genotypes across healthy individuals, though frequencies vary across different continental ancestries.
Frequently asked questions
Does having the rs110404 variant mean I will develop anxiety?
No. The rs110404 variant is a common genetic polymorphism, not a causal genetic mutation. While research suggests it may modestly influence cortisol regulation in response to stress, complex psychological traits such as anxiety are governed by hundreds of genes together with environmental life experiences.
Can testing for rs110404 guide my psychiatric medications?
No validated clinical guidelines or pharmacogenomic dosing protocols exist for rs110404. Current clinical dosing recommendations focus on well-established drug-metabolizing enzymes and transporters. Always consult your prescribing physician or pharmacist before starting, changing, or discontinuing any medication.
How does CRHR1 affect stress levels in the body?
The CRHR1 gene provides instructions for a receptor protein that detects corticotropin-releasing hormone, triggering the pituitary gland to signal adrenal cortisol release. Variants in this gene can subtly alter the sensitivity or tone of the hypothalamic-pituitary-adrenal (HPA) axis, influencing how the body initiates its hormonal response to psychological stress.
Why is the evidence for rs110404 considered limited?
Much of the evidence originates from smaller candidate-gene and gene-by-environment interaction studies that show mixed findings across different cohorts. Modern large-scale genome-wide association studies have not found large, standalone diagnostic effects for this individual variant, meaning its real-world contribution to mood disorders is modest and context-dependent.
Sources & further reading
Educational information only, last refreshed 9/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs110404?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CRHR1
HPA-axis modulating variant in CRHR1 that interacts with psychosocial stress exposure to affect emotional reactivity and stress-coping traits.
Key intronic polymorphism in the corticotropin-releasing hormone receptor 1 gene that moderates endocrine and emotional vulnerability after exposure to early life trauma.
Polymorphism within the CRHR1 locus tagged to haplotypes modulating cortisol release during the Trier Social Stress Test.
Variant in the corticotropin-releasing hormone receptor 1 gene that moderates hypothalamic-pituitary-adrenal axis reactivity and vulnerability to stress-induced mood disturbances.
Intronic CRHR1 variant associated with neuroendocrine stress sensitivity.
Tag variant in the CRHR1 locus associated with HPA axis regulation.